BioPharma, Policy Roche completes acquisition of Spark Therapeutics as regulators give go-ahead By Alaric DeArment
BioPharma Spark Therapeutics’ new FDA approval shows gene therapies are officially on fire By Juliet Preston
Startups, BioPharma Spark Therapeutics acquires retinitis pigmentosa gene therapy for $15M By Meghana Keshavan
Daily Spark Therapeutics adds regulatory insider to support gene therapy for retinal degeneration By Stephanie Baum
Hospitals Spark Therapeutics’ late-stage gene therapy for inherited blindness takes a $73M step forward By
Daily Gene therapy company Spark Therapeutics inks licensing deal for a retinitis pigmentosa gene therapy By Stephanie Baum
Artificial Intelligence, BioPharma Diagonal Therapeutics’ New Slant Attracts $128M to Reactivate Antibody Drug R&D By Frank Vinluan
BioPharma, Pharma Viking Therapeutics Obesity Drug’s Data Raise Best-in-Class Expectations By Frank Vinluan
BioPharma, Pharma Digital Medicines Sector Draws Lessons From Pear Therapeutics’ Demise By Frank Vinluan
BioPharma, Devices & Diagnostics Rigorous Data Are Key to Convince Payers, Investors in the World of Digital Therapeutics By Frank Vinluan
BioPharma, Pharma Orbital Therapeutics Raises $270M to Bring RNA-Based Medicines to New Heights By Frank Vinluan
BioPharma, Pharma Startup Nuvig Therapeutics gets $47M to bring immune system back into balance By Frank Vinluan
BioPharma, Pharma Werewolf cancer drug strikes right note with Jazz Pharma, sparking licensing deal By Frank Vinluan
